Claims

1. A combination comprising at least one potato derived protease inhibitor and dexpanthenol, its pharmaceutically acceptable salts or a mixture thereof.
2. The combination according to claim 1, wherein the quantity of said at least one potato derived protease inhibitor or a mixture thereof is between 0.1% and 20% of the combination.
3. The combination according to claim 1, wherein the quantity of said at least one potato derived protease inhibitor or a mixture thereof is between 5 to 15% of the combination.
4. The combination according to claim 1, wherein the quantity of said at least one potato derived protease inhibitor or a mixture thereof is between 4 to 10% of the combination.
5. The combination according to claim 1, wherein the quantity of dexpanthenol, its pharmaceutically acceptable salts or a mixture thereof is between 0.01% and 40% of the combination.
6. The combination according to claim 1, wherein the quantity of dexpanthenol, its pharmaceutically acceptable salts or a mixture thereof is between 2 to 25% of the combination.
7. The combination according to claim 1, wherein the quantity of dexpanthenol, its pharmaceutically acceptable salts or a mixture thereof is between 4 to 25% of the combination.
8. Use of the combination according to any one of claims 1 to 7, in the manufacture of a medicament for the prevention and/or treatment of skin damage caused by urine and/or faeces and as adjuvant in skin repair.
9. The use according to claim 8, wherein said skin damage is perineal, perianal inflammation or dermatitis present in premature babies, babies or other adult patients.
10. The combination according to any one of claims 1 to 7, or the use according to claim 8 or claim 9, further comprising an additional active principle, selected from antimicotics, antiseptics and disinfectants, surfactants and defoamers, skin soothing agents, anti-inflammatory, anti-bacterial, antihistamine and antioxidants and/or vitamins.

11. A pharmaceutical composition comprising the combination of any one of claims 1 to 7, together with pharmaceutically acceptable excipients and/or adjuvants.
12. The pharmaceutical composition according to claim 11, wherein it contains from 0.1% to 50% of said combination.
13. The pharmaceutical composition according to claim 12, wherein it contains from 0.01% to 20% of said combination.
14. Use of the pharmaceutical composition according to any one of claims 11 to 13, in the manufacture of a medicament for the prevention and/or treatment of skin damage caused by urine and/or faeces and as adjuvant in skin repair.
15. The use according to claim 14, wherein the medicament is to be used simultaneously, separately or sequentially in the prevention and/or treatment of skin damage caused by urine and/or faeces and as adjuvant in skin repair.
16. The use according to claim 14, wherein the medicament is to be administered topically.
17. The use according to claim 16, wherein the form of the medicament is selected from cream, ointment, gel, foam, powder, spray and gauzes.
18. The use according to claim 17, wherein the form of the medicament is selected from cream or ointment.